Renovo Concepts, Inc. Names New CEO Brad Mathis to Lead Commercialization Efforts

August 1, 2024 – [San Antonio] – Renovo Concepts, Inc. (“Renovo” or “the Company”) announced today the hiring of highly-accomplished biotech executive Bradley K. Mathis as Chief Executive Officer, effective immediately. “Brad’s background and experience make him the ideal candidate to lead our next phase of development and growth,” stated Michael Morykwas, PhD co-founder and Chief Scientific Officer of Renovo. Mr. Mathis has over 30 years of global and domestic experience in product launch planning and oversight, commercialization and sales, marketing, clinical operations and business development with small and large biotech organizations including, Amgen, Celgene and Bristol-Myers Squibb. Most recently, Mathis served as Chief Operations Officer of Entropy Bio, an early-stage drug development company focused on a resistance platform combining existing and novel assets into highly-impactful clinical combinations. Renovo recently received an Investigational Device Exemption from the U.S. Food and Drug Agency and is currently proceeding to patient enrollment in a Phase I clinical trial of its novel Mechanical Tissue Resuscitation (“MTR”) device.

About Renovo Concepts

Formed in 2017, Renovo Concepts develops and manufactures a novel MTR platform technology to actively remove excess fluids in damaged tissues of the brain, heart and spine to help mitigate the risk of secondary tissue/organ injury. Utilizing controlled application of sub-atmospheric (negative) pressure in the treatment of injuries, MTR offers a new therapeutic modality in a field that has seen little innovation in treatment protocols over many years.